Botanical species · safety record

Ardisia japonica

The EFSA Compendium of Botanicals holds 6 constituent measurements for Ardisia japonica. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Ardisia japonica (Thunb.) Blume

6Constituent measurements

0Safety records

5Cited sources

2Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 2 licensed products naming Ardisia japonica as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Chrysophanol	Live plants	Solvent extraction	—	Unspecified	Resolve DOI
Pentacyclic triterpene saponins	Live plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Physcion	Live plants	Solvent extraction	—	Unspecified	Resolve DOI
Benzoquinones	Roots and other underground parts	Solvent extraction	—	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Embelin	Live plants	Solvent extraction	—	Unspecified	No resolvable identifier
Pentacyclic triterpene glycosides	Aerial part of plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

FUKUYAMA, Y., KIRIYAMA, Y., OKINO, J., KODAMA, M., IWAKI, H., HOSOZAWA, S., MATSUI, K. NATURALLY-OCCURRING 5-LIPOXYGENASE INHIBITOR .2. STRUCTURES AND SYNTHESES OF ARDISIANONE-A AND ARDISIANONE-B, AND MAESANIN, ALKENYL-1,4-BENZOQUINONES FROM THE RHIZOME OF ARDISIA-JAPONICA . Chemical & pharmaceutical bulletin, 1993, vol. 41, no. 3, p. 561-565.
De Tommasi, N., Piacente, S., De Simone, F., Pizza, C., Zhou, Z.L. Characterization of three new triterpenoid saponins from Ardisia japonica. Journal of natural products, 1993, vol. 56, no. 10, p. 1669-1675.
Chang, Xiaolong., Li, Wei., Jia, Zhonghua., Satou, Tadaaki., Fushiya, Shinji., Koike, Kazuo. Biologically active triterpenoid saponins from Ardisia japonica. Journal of natural products, 2007, vol. 70, no. 2, p. 179-187. DOI
Li, YF., Hu, LH., Lou, FC., Li, J., Shen, Q. PTP1B inhibitors from Ardisia japonica. Journal of asian natural products research, 2005, vol. 7, no. 1, p. 13-18. DOI
Edderkaoui, Mouad., Lugea, Aurelia., Hui, Hongxiang., Eibl, Guido., Lu, Qing-Yi., Moro, Aune., Lu, Xuyang., Li, Gang., Go, Vay-Liang., Pandol, Stephen J. Ellagic Acid and Embelin Affect Key Cellular Components of Pancreatic Adenocarcinoma, Cancer, and Stellate Cells.. Nutrition and cancer, 2013, vol. 65, no. 8, p. 1232-1244.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature